Cost-Effectiveness of the Adjuvant Recombinant Zoster Vaccine in Japanese Adults Aged 65 Years and Older

Cost-Effectiveness of the Adjuvant Recombinant Zoster Vaccine in Japanese Adults Aged 65 Years and Older

Abstract Introduction The incidence of herpes zoster (HZ) rises steeply after the age of 50 years and the number of HZ cases and complications such as postherpetic neuralgia (PHN) is predicted to increase because of the ageing population. The objective of this study was to estimate the cost-effectiv...

Full description

Bibliographic Details
Main Authors: Makoto Shiragami, Akiko Mizukami, Toshihiko Kaise, Desmond Curran, Desiree Van Oorschot, Benjamin Bracke, Daisuke Watanabe
Format: Article
Language:English
Published: Adis, Springer Healthcare 2019-03-01
Series:Dermatology and Therapy
Subjects:
Cost-effectiveness
Herpes zoster
Incremental cost-effectiveness ratio
Markov model
Postherpetic neuralgia
Quality-adjusted life years
Online Access:http://link.springer.com/article/10.1007/s13555-019-0291-4

Similar Items

Similar Items